181 related articles for article (PubMed ID: 37605068)
1. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome.
Simbrunner B; Villesen IF; Scheiner B; Paternostro R; Schwabl P; Stättermayer AF; Marculescu R; Pinter M; Quehenberger P; Trauner M; Karsdal M; Lisman T; Reiberger T; Leeming DJ; Mandorfer M
Hepatol Int; 2023 Dec; 17(6):1532-1544. PubMed ID: 37605068
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.
Pomej K; Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Bauer D; Pereyra D; Starlinger P; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Reiberger T; Mandorfer M
Dig Liver Dis; 2022 Oct; 54(10):1376-1384. PubMed ID: 35871985
[TBL] [Abstract][Full Text] [Related]
4. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
[TBL] [Abstract][Full Text] [Related]
5. Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
Islek A; Ilhan D; Ozturk N; Guven B; Sag E
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e951-e956. PubMed ID: 33369998
[TBL] [Abstract][Full Text] [Related]
6. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
[TBL] [Abstract][Full Text] [Related]
7. The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.
Scheiner B; Northup PG; Gruber AB; Semmler G; Leitner G; Quehenberger P; Thaler J; Ay C; Trauner M; Reiberger T; Lisman T; Mandorfer M
Liver Int; 2020 Jun; 40(6):1415-1426. PubMed ID: 32052552
[TBL] [Abstract][Full Text] [Related]
8. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response.
Simbrunner B; Caparrós E; Neuwirth T; Schwabl P; Königshofer P; Bauer D; Marculescu R; Trauner M; Scheiner B; Stary G; Mandorfer M; Reiberger T; Francés R
Hepatol Int; 2023 Aug; 17(4):1045-1056. PubMed ID: 36881247
[TBL] [Abstract][Full Text] [Related]
9. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.
Zou Z; Yan X; Li C; Li X; Ma X; Zhang C; Ju S; Tian J; Qi X
BMJ Open; 2019 Aug; 9(8):e025656. PubMed ID: 31473610
[TBL] [Abstract][Full Text] [Related]
10. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
Costa D; Simbrunner B; Jachs M; Hartl L; Bauer D; Paternostro R; Schwabl P; Scheiner B; Stättermayer AF; Pinter M; Trauner M; Mandorfer M; Reiberger T
J Hepatol; 2021 Apr; 74(4):819-828. PubMed ID: 33075344
[TBL] [Abstract][Full Text] [Related]
11. Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease.
Dominik N; Scheiner B; Zanetto A; Balcar L; Semmler G; Campello E; Schwarz M; Paternostro R; Simbrunner B; Hofer BS; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Simioni P; Reiberger T; Mandorfer M
Aliment Pharmacol Ther; 2024 Jun; 59(11):1376-1386. PubMed ID: 38482706
[TBL] [Abstract][Full Text] [Related]
12. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
[TBL] [Abstract][Full Text] [Related]
13. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD.
Paternostro R; Kwanten WJ; Hofer BS; Semmler G; Bagdadi A; Luzko I; Hernández-Gea V; Graupera I; García-Pagán JC; Saltini D; Indulti F; Schepis F; Moga L; Rautou PE; Llop E; Téllez L; Albillos A; Fortea JI; Puente A; Tosetti G; Primignani M; Zipprich A; Vuille-Lessard E; Berzigotti A; Taru MG; Taru V; Procopet B; Jansen C; Praktiknjo M; Gu W; Trebicka J; Ibanez-Samaniego L; Bañares R; Rivera-Esteban J; Pericas JM; Genesca J; Alvarado E; Villanueva C; Larrue H; Bureau C; Laleman W; Ardevol A; Masnou H; Vanwolleghem T; Trauner M; Mandorfer M; Francque S; Reiberger T;
J Hepatol; 2024 May; ():. PubMed ID: 38823501
[TBL] [Abstract][Full Text] [Related]
14. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease.
Simbrunner B; Stadlmann A; Schwabl P; Paternostro R; Bauer DJM; Bucsics T; Scheiner B; Lampichler K; Wöran K; Beer A; Eigenbauer E; Pinter M; Stättermayer AF; Marculescu R; Szekeres T; Trauner M; Mandorfer M; Reiberger T
Dig Liver Dis; 2021 Mar; 53(3):345-352. PubMed ID: 33032973
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
Mandorfer M; Schwabl P; Paternostro R; Pomej K; Bauer D; Thaler J; Ay C; Quehenberger P; Fritzer-Szekeres M; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferlitsch A;
Aliment Pharmacol Ther; 2018 Apr; 47(7):980-988. PubMed ID: 29377193
[TBL] [Abstract][Full Text] [Related]
16. An impaired pituitary-adrenal signalling axis in stable cirrhosis is linked to worse prognosis.
Hartl L; Simbrunner B; Jachs M; Wolf P; Bauer DJM; Scheiner B; Balcar L; Semmler G; Schwarz M; Marculescu R; Trauner M; Mandorfer M; Reiberger T
JHEP Rep; 2023 Aug; 5(8):100789. PubMed ID: 37484210
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg.
Jindal A; Sarin SK; Kumar M; Kumar G
Dig Dis Sci; 2022 Nov; 67(11):5280-5289. PubMed ID: 35113276
[TBL] [Abstract][Full Text] [Related]
18. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
Reiniš J; Petrenko O; Simbrunner B; Hofer BS; Schepis F; Scoppettuolo M; Saltini D; Indulti F; Guasconi T; Albillos A; Téllez L; Villanueva C; Brujats A; Garcia-Pagan JC; Perez-Campuzano V; Hernández-Gea V; Rautou PE; Moga L; Vanwolleghem T; Kwanten WJ; Francque S; Trebicka J; Gu W; Ferstl PG; Gluud LL; Bendtsen F; Møller S; Kubicek S; Mandorfer M; Reiberger T
J Hepatol; 2023 Feb; 78(2):390-400. PubMed ID: 36152767
[TBL] [Abstract][Full Text] [Related]
19. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
Reuken PA; Kussmann A; Kiehntopf M; Budde U; Stallmach A; Claus RA; Bruns T
Liver Int; 2015 Jan; 35(1):37-45. PubMed ID: 25113276
[TBL] [Abstract][Full Text] [Related]
20. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
